IMV (IMV.US), a biopharmaceutical company, rose 10.94% to $3.380 before Monday's trading in the U.S., according to Zhitong Financial APP. The company announced the completion of a preclinical study of its health event candidate vaccine DPX-COVID-19, confirming its good safety and protective potential against the virus.

IMV said its candidate vaccine would be stable for at least three months at room temperature between 2 °C and 8 °C. The company is working with global manufacturing partners and is starting to expand its vaccine production in India and Europe to increase production.

The company plans to conduct supplementary preclinical studies, including testing for newly mutated viruses, and will provide up-to-date information on its clinical research plans in the first quarter of 2021.